Navigation Links
Bionovo Reports Third Quarter 2008 Financial Results

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced results for the third quarter of 2008.

Quarter Results

The company did not report any revenue for the three and nine months ended September 30, 2008.

Total operating expenses for the three and nine months ending September 30, 2008 were $5.2 million and $13.7 million, respectively, compared to $3.6 million and $9.9 million, respectively, for the same period in 2007. This reflects the increase in costs related to the clinical trials of our leading drug candidates.

The Company reported a net loss for the three and six months ended September 30, 2008 of $5.1 million, or $0.07 per share, and $13.2 million, or $0.17 per share, respectively, compared with a net loss of $3.2 million, or $0.05 per share, and $9.2 million, or $0.15 per share, respectively, for the same periods in 2007.

The Company ended the quarter with $17.3 million in cash, cash equivalents and short term investments, and began the quarter with $24.6 million, a difference of $7.3 million. This difference includes $3.4 million in non- recurring capital expenditures associated with tenant improvements for laboratory and production capability expansion.

Company Highlights

The Company has continued the scientific and clinical development of its drug candidates for the treatment of advanced breast cancer, menopausal hot flashes, and menopausal vaginal atrophy. Recent advances have included:

-- The Phase 1 portion of the BZL101 Phase 1/2 clinical trial for

advanced metastatic breast cancer has now been completed

successfully, showing positive safety and tolerability profiles, as

well as the early signs of clinical efficacy. The Phase 2 part of

the trial is now open for enrollment at 17 clinical sites in the

U.S., and is expected to enroll 80 patients in the trial. There are

currently over 160,000 women living with metastatic breast cancer in

the U.S.

-- The Company presented an analysis of the metabolism of one of the

active chemical ingredients of MF101, the Company's drug candidate

for the treatment of menopausal hot flashes. The presentation, to

the American Society for Pharmacology and Experimental Therapeutics,

Drug Metabolism and Disposition, adds to the growing body of data

supporting MF101's mechanism of action, safety and potential

potency, as well as furthering the intellectual property protection

for the Company.

-- Also on MF101, the Company released data from its previous Phase 2

study that showed MF101's superior efficacy with respect to "night

sweats" or "night awakenings due to hot flashes" -- a particularly

debilitating form of hot flash for which many women seek medical

treatment and improved quality of life. This adds to the increasing

evidence of the possible efficacy of MF101 and the market

opportunity awaiting MF101 if and when it is approved by the FDA and

put on the market.

-- The Company is currently in discussions with the FDA on the specific

requirements for progression to Phase 3 pivotal trials of MF101. The

Company expects to have resolution, and to be in a position to

continue the clinical development and trials for MF101, by the end

of the year.

-- The Company presented a report to the North American Menopause

Society (NAMS), showing laboratory results of superior efficacy for

VG101, the Company's drug candidate for menopausal vaginal dryness,

over other treatments. The Company expects to begin human clinical

trials for VG101 late in 2008 or early in 2009.

"The third quarter of the year continued the positive scientific progress for Bionovo," said Dr. Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "After much preparation and discussion with the FDA and our advisors, we are now poised to begin the next phase of clinical testing for our portfolio of women's health and oncology drug candidates. We are also continuing promising discussions with potential pharmaceutical partners."

"With over seventeen million dollars in cash, cash equivalents and short- term investments, and a lower than industry clinical trial cost profile, we are poised to progress our lead drug candidates through these challenging economic times," added Tom Chesterman, Bionovo's Senior Vice President and Chief Financial Officer. "Given our current plans and expectations, this funding will be sufficient for at least the next 12 months"

A full financial report on Form 10-Q is expected to be filed by Tuesday, November 4, 2008.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Bionovo, Inc

(A Development Stage Company)

Condensed Statements of Operations


Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Revenues $- $243,375 $- $250,875

Operating expenses:

Research and

development 3,941,303 2,444,674 8,881,340 7,212,445

General and

administrative 1,222,319 1,129,402 4,852,648 2,689,246

Merger cost - - - -



expenses 5,163,622 3,574,076 13,733,988 9,901,691

Loss from

operations (5,163,622) (3,330,701) (13,733,988) (9,650,816)

Change in fair

value of warrant

liability - - - -

Interest income 142,815 170,272 638,562 517,958

Interest expense (36,286) (42,370) (98,198) (68,898)

Other income

(expense) (1,322) (5,241) (16,938) (5,241)

Loss before

income tax (5,058,415) (3,208,040) (13,210,562) (9,206,997)

Income tax

provision - - (3,256) (2,400)

Net loss $(5,058,415) $(3,208,040) $(13,213,818) $(9,209,397)

Basic and

diluted net

loss per common

share $(0.07) $(0.05) (0.17) (0.15)

Shares used in

computing basic

and diluted net

loss per common

share 76,363,100 65,571,108 76,350,180 63,368,561

Accumulated from

February 1, 2002

(Date of Inception) to

September 30, 2008

Revenues $659,490

Operating expenses:

Research and development 24,673,545

General and administrative 12,304,415

Merger cost 1,964,065

Total operating expenses 38,942,025

Loss from operations (38,282,535)

Change in fair value of warrant liability 831,288

Interest income 1,706,979

Interest expense (335,216)

Other income (expense) 127,959

Loss before income tax (35,951,525)

Income tax provision (12,258)

Net loss $(35,963,783)

Basic and diluted net loss per common share $(0.88)

Shares used in computing basic and diluted

net loss per common share 40,805,306

Bionovo, Inc

(A Development Stage Company)

Condensed Balance Sheets

September 30, December 31,

2008 2007

(Unaudited) (Note 1)


Current assets:

Cash and cash equivalents $6,664,427 $28,472,485

Short-term investments 10,645,621 4,823,938

Receivables 262,233 285,899

Prepaid expenses and other current assets 1,159,263 405,381

Total current assets 18,731,544 33,987,703

Property and equipment, net 6,777,308 3,900,248

Other assets and patent pending, net 1,027,306 277,220

Total assets $26,536,158 $38,165,171


Current liabilities:

Accounts payable $881,452 $299,677

Accrued clinical and costs of other studies 102,814 298,559

Accrued compensation and benefits 870,435 462,485

Current portion of lease obligation 793,242 706,710

Other current liabilities 467,088 949,200

Total current liabilities 3,115,031 2,716,631

Non-current portion of lease obligation 693,519 526,346

Commitments and contingencies

Shareholders' equity:

Preferred stock, $0.0001 par value;

10,000,000 shares authorized; none issued

and outstanding - -

Common stock, $0.0001 par value,

190,000,000 shares authorized; 76,363,101

and 76,343,101 shares issued and outstanding

as of September 30, 2008 and December 31,

2007, respectively 7,636 7,634

Additional paid-in capital 58,737,205 57,660,045

Accumulated other comprehensive income (53,450) 4,480

Accumulated deficit (35,963,783) (22,749,965)

Total shareholders' equity 22,727,608 34,922,194

Total liabilities and shareholders'

equity $26,536,158 $38,165,171

* The balance sheet at December 31, 2007 has been derived from the audited

financial statements at that date but does not include all of the

information and footnotes required by accounting principles generally

accepted in the United States for complete financial statements.

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which ... video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading ... around the world, is giving back to cancer research with a month-long promotion supporting ... Now through October 31, shoppers can use promo code PinkRibbon to get 10 percent ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):